R289

Small molecule

Earlyevidence

Evidence outlook

Early-stage evidence only

Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 1/2 (1)
Myelodysplastic Syndromes

Competitive landscape

This drug's own stage for Myelodysplastic Syndromes: Phase 1/2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
R289: this drugPhase 1/2Small moleculeIRAK1/IRAK4not yet gradedNo reviewed efficacy summary in this indication
AzacitidineApprovedSmall moleculeDNMT1 (DNA methyltransferase 1)not yet gradedNo reviewed efficacy summary in this indication
Decitabine / Cedazuridine (Inqovi)ApprovedSmall moleculeDecitabine/cedazuridine fixed combination (DNMT + CDA inhibition)Partial signalFeatured results are non-efficacy only in this race
Imetelstat (Rytelo)ApprovedRNA / oligonucleotideTelomeraseReliable signalNo reviewed efficacy summary in this indication
LenalidomideApprovedSmall moleculeCereblon E3 ubiquitin-ligase, Thalidomide Analognot yet gradedNo reviewed efficacy summary in this indication
ElriterceptPhase 3UndisclosedActivin A/Bnot yet gradedNo reviewed efficacy summary in this indication
Roxadustat (Evrenzo)Phase 3Small moleculeHIF prolyl hydroxylase (HIF-PH1/2/3)not yet gradedNo reviewed efficacy summary in this indication
AND017Phase 2Small moleculeHIF prolyl hydroxylase (HIF-PH1/2/3)not yet gradedNo reviewed efficacy summary in this indication
MomelotinibPhase 2Small moleculeJAK1 / JAK2 / ACVR1not yet gradedNo reviewed efficacy summary in this indication
PF-08046040
—(overall)
UndisclosedCD70, CD70, CD70, CD70, CD70, CD70, CD70, CD70, CD70, CD70, CD70, CD70, CD70, CD70, CD70, CD70not yet gradedNo reviewed efficacy summary in this indication
REGN17235
—(overall)
Multispecific antibodySLC3A2 x CD3not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow R289 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
December 2027 (1)
Phase 1/2Myelodysplastic SyndromesRecruiting
Est. primary completion 2027-12 · NCT05308264 · CT.gov ↗
What to watch

See the full readout calendar ↗